Malignant transformation in vestibular schwannoma: report of a single case, literature search, and debate

Case report

CHARALAMPOS SEFERIS, M.D.,¹ MICHAEL TORRENS, F.R.C.S.,¹
CHRYSSA PARASKEVOPOULOU, M.Sc.,¹ AND GEORGIOS PSICHIDIS, M.D.²

¹Gamma Knife Department, Hygeia Hospital, Athens; and ²Department of Neurosurgery, Diavalkaniko Hospital, Thessaloniki, Greece

Object. The significance of radiation in the induction of malignancy in vestibular schwannomas (VSs) after radiosurgery is unclear despite an increasing number of case reports. The authors describe a new case of verified malignant transformation in a vestibular schwannoma (MTVS) and provide a new evaluation of such cases previously reported in the literature.

Methods. A 46-year-old woman underwent subtotal resection of a right-sided VS in 2004. The histological characteristics of the lesion were typical and benign. In early 2007 Gamma Knife surgery (GKS) was performed to treat a residual enlarging remnant. The radiosurgery parameters included the following: target volume 3.5 cm³, prescription dose 12 Gy, prescription isodose 45%, maximum dose 26.7 Gy, and coverage 97%. At 2 years' follow-up the lesion was enlarged to 5.2 cm³, but by 5 years it had decreased to 2.3 cm³. Six months later the lesion was 8.4 cm³. Repeated surgery was performed, and a histological analysis revealed a malignant peripheral nerve sheath tumor. The case was further managed with repeated GKS performed in the spring of 2013. At that time, the radiosurgery parameters included the following: target volume 3.5 cm³, prescription dose 16 Gy, prescription isodose 45%, maximum dose 35.6 Gy, and coverage 91%. This Gamma Knife Department has treated a total of 205 patients with VS (local incidence of MTVS 0.49%). A search of the literature published up to and including 2013 was performed using PubMed as well as more informal search methods.

Results. This patient is the 29th reported case of MTVS after radiation therapy. Of these cases, 40.7% were patients with neurofibromatosis (NF). In those cases in which histology showed tumors with previously benign characteristics, totally conforming to the criteria for MTVS, the mean delay to malignant expression was 68 months (median delay 72 months). The authors also retrieved papers reporting 30 cases of malignant VS in patients who had not undergone radiation treatment. Five of those cases were malignant transformation of a benign entity, and in 4 of them histology had verified that the initial disease was benign. In those 4 cases, there was a mean delay to malignant expression of 7.2 months (median delay 8 months).

Conclusions. Despite more frequent reports of MTVS after radiation treatment recently, there has been no accurate quantification of the risk, except in patients with NF, in whom the incidence of malignancy is high in relation to the numbers treated. The present analysis indicates that the risk of malignancy over 20 years in cases in which no radiation treatment has occurred is 1.32–2.08 per 100,000, and this risk decreases to 1.09–1.74 per 100,000 if cases of NF are excluded. After radiation treatment, the overall risk over 20 years is 25.1 per 100,000, and this risk decreases to 15.6 per 100,000 if cases of NF are excluded. Radiation treatment increases the risk by approximately 10 times in non-NF cases.

(<http://thejns.org/doi/abs/10.3171/2014.7.GKS141311>)

KEY WORDS • stereotactic radiosurgery • Gamma Knife surgery • malignant transformation • vestibular schwannoma

DESPITE more frequent reports of malignant transformation of vestibular schwannoma (MTVS) after radiation treatment over the last 5 years,^{2,10,13,22,}

^{36,43,46,51,57,61,62} the quantitated significance of this radiation induction has not been clarified, except in cases of neurofibromatosis Type 2 (NF2) in which the incidence of malignancy is high in relation to the number of patients treated.⁵ An excellent population study of nearly 5000 cases from Sheffield, England,⁴⁷ suggested that there was no increased rate of malignancy of any kind after radiosurgery, but naturally such a study will not detect events with a probability of less than 1:5000.

Abbreviations used in this paper: GKS = Gamma Knife surgery; MPNST = malignant peripheral nerve sheath tumor; MTVS = malignant transformation of vestibular schwannoma; NF = neurofibromatosis; NF2 = neurofibromatosis Type 2; SRS = stereotactic radiosurgery; VS = vestibular schwannoma.

Malignant transformation after radiosurgery

Prompted by the occurrence in our department of a case of an MTVS that conformed fully to Cahan's criteria for radiation-induced tumors,⁷ we conducted a literature search to identify other cases and compiled a list significantly larger than previous reviews.

Case Report

A 46-year-old woman with no evidence of NF2 presented with impaired hearing in 2003, and in mid-2004 underwent subtotal resection of a right-sided vestibular schwannoma (VS). The histological characteristics of the tumor were benign. Postoperatively, the patient exhibited a House-Brackmann Grade IV facial paresis and had no residual hearing on the right side.

In 2007 a residual enlarging tumor remnant was noted on MR imaging and GKS was performed. The radiosurgery parameters at the time included the following: target volume 3.5 cm³, prescription dose 12 Gy, prescription isodose 45%, maximum dose 26.7 Gy, coverage 97%, Paddick Conformity Index 0.8, and Gradient Index 3.0. At the 2-year follow-up in 2009, MR imaging showed that the lesion had enlarged to 5.2 cm³, but by 2012 it had decreased to 2.3 cm³. Six months later, an MR imaging examination showed that the lesion had grown rapidly to 8.4 cm³. Repeated partial excision was performed, and a new histological analysis revealed a malignant peripheral nerve sheath tumor (MPNST) with MIB-1 positivity in 30% of the cells. Immunohistochemical analysis of the tumor cells showed a general positive reaction for vimentin and a focal positive reaction for S-100 protein, but negative reactions for CD56, CD34, EMA, and GFAP. The delay in onset from radiosurgical treatment to presentation of malignant transformation totaled 66 months.

In the spring of 2013 the surgical remnant was treated again with GKS. The radiosurgery parameters at that time were as follows: target volume 3.5 cm³, prescription dose 16 Gy, prescription isodose 45%, maximum dose 35.6 Gy, coverage 91%, Paddick Conformity Index 0.7, and Gradient Index 2.8. In 2014, at the patient's 6-month follow-up examination, no change in the tumor was found, and no new cranial nerve or other neurological deficit had developed.

A literature search was performed using the terms malignant, transformation, radiosurgery, vestibular, acoustic, schwannoma, neuroma, and malignant peripheral nerve sheath tumor/MPNST on PubMed together with a search and cross-check using Google Scholar. In addition, detailed contents of the publications retrieved in the search were cross-checked, because in some instances the same cases were reported in more than one journal by different authors.

Results

A total of 59 cases of MPNST of the vestibular nerve were reported in the literature: 29 cases occurred after radiation treatment, 25 cases arose spontaneously, and 5 cases occurred after surgery for benign disease. The details of these cases are summarized in Tables 1–3. The

two largest collected series reported previously included 23 cases⁵⁷ and 35 cases.³² Of the 29 cases of MPNST that occurred after radiation treatment, 11 (40.7%) of 26 patients in whom there was available information suffered from NF (Table 1). The average patient age was 40.4 years; 14 patients were female, 10 were male, and gender was not stated for the remaining 5 patients. The histological appearance of the tumor was MPNST in 19 patients, triton tumor in 3 patients, rhabdomyosarcoma in 1 patient, and MPNST with sarcomatous differentiation in 4 patients. In 2 cases the histological type of lesion was not clarified, but the progression was clearly malignant. Twenty-six cases had been treated by stereotactic radiosurgery (SRS) and 3 others by other forms of radiation therapy. In only 9 cases had histology proved the tumor benign before radiation treatment was performed. In the other cases there was no biopsy or the histological findings were not recorded. The overall mean delay from radiation treatment to malignant expression was 85 months. In those cases with documented prior benign histological findings that totally conformed to Cahan's criteria,⁷ the mean delay from radiation treatment to malignant expression was 68 months. The criteria for malignant transformation, as originally outlined by Cahan et al.,⁷ are as follows: 1) benign histological type must be proven before irradiation; 2) there must be a prolonged latency period, usually greater than 4 years, between radiation delivery and tumor development; 3) the tumor must arise in the irradiated field; 4) the tumor must be histologically distinct from the original tumor; and 5) the patient must not have a genetic predisposition to the development of cancer.

Of the 30 cases that occurred without previous radiation treatment, 5 (17%) of 29 patients suffered from NF (Tables 2 and 3). Thirteen patients were female, 14 were male, and sex was not stated for 3 patients. The average age of these patients was 43.2 years in the 25 patients in whom malignancy occurred spontaneously and 59 years in the 5 cases of MTVS. The histological tumor appearance was MPNST in 23 patients, triton tumor in 4 patients, and MPNST with melanomatous differentiation in 3 patients. In 4 cases the histological findings had proved to be benign at some time before the malignant condition appeared, and in these cases the mean delay to malignant expression was 7.2 months.

The chronology of published reports on the various cases was analyzed by dates of publication, and the results are shown in Table 4. It is evident that the incidence of cases in the three 5-year periods beginning in the year 2000 (43 cases) is approximately 3 times greater than the incidence of cases in the three 5-year periods before 2000 (15 cases). The millennium year, 2000, occurred 10 years after significant numbers of radiosurgical treatments for VS began to be performed.

Discussion

The case that we have described represents the 9th reported case of MTVS after radiation treatment that conforms fully to Cahan's criteria and the 29th case of MPNST occurring after radiotherapy or radiosurgery.

The topic most in need of evaluation is the determi-

TABLE 1: Malignant transformation following radiation treatment*

Authors & Year	Age (yrs), Sex	NF	Type of RT	Histological Type	Cahan Criteria	Latency (mos)
Akamatsu et al., 2010	67, F	no	SRS	MPNST	yes	90
Bari et al., 2002	28, F	yes	SRS	MPNST		48
Baser et al., 2000	NS, NS	yes	SRS	MPNST		NS
	NS, NS	yes	SRS	MPNST		NS
	NS, NS	yes	SRS	MPNST		NS
Carlson et al., 2010	25, F	yes	SRS	triton		120
Comey et al., 1998	50, M	no	SRS	rhabdomyosarcoma		60
Demetriades et al., 2010	37, M	no	SRS	MPNST	yes	120
Hanabusa et al., 2001	51, F	no	SRS	sarcoma	yes	6
Hasegawa et al., 2013	NS, NS	NS	SRS	MPNST		NS
Ho & Kveton, 2002	14, F	yes	SRS	NS		7
Kubo et al., 2005	55, M	no	SRS	MPNST		NS
Maire et al., 2006/Markou et al., 2012	45, F	no	CRT	MPNST		231
McEvoy & Kitchen, 2003	22, M	yes	SRS	NS		24
Muracciole et al., 2004	61, F	no	SRS	triton		72
Newell & Pollack, 2012	50, M	no	yes	MPNST		NS
Norén, 1998	18, F	yes	SRS	MPNST		60
Pollock et al., 1998	NS, NS	NS	SRS	triton		NS
Puataweepong et al., 2012	34, F	no	SRS	MPNST		72
Scheithauer et al., 2009	32, M	yes	CRT	MPNST		324
Schmitt et al., 2011	51, M	no	SRS	sarcoma		87
Shin et al., 2002; Kurita 1997†	26, F	no	SRS	MPNST	yes	72
Tanbouzi Hussein et al., 2011	20, M	yes	SRS	MPNST		60
Thomsen et al., 2000	19, F	yes	SRS	sarcoma	yes	72
Van Rompaey et al., 2009	53, F	no	SRS	MPNST		96
Wilkinson et al., 2004	53, M	no	SRS	MPNST	yes	48
Yanamadala et al., 2013	51, F	no	SRS	MPNST	yes	60
Yang et al., 2010	74, M	no	SRS	sarcoma	yes	72
present case	34, F	no	SRS	MPNST	yes	72

* CRT = conformal radiotherapy; NF = evidence of neurofibromatosis; NS = not stated; RT = prior exposure to radiation; SRS = stereotactic radiosurgery.

† Kurita H, et al: Malignant transformation of a vestibular schwannoma after gamma knife radiosurgery. Poster presentation at the Third Congress of International Stereotactic Radiosurgery Meeting, Madrid, 1997.

nation of the significance of radiation in the induction of malignancy, which up to now has not been quantified precisely. With reported numbers of malignant VSs in the radiation-treated population being the same as the numbers of malignant VSs in the immensely larger, non-radiation-treated population, the effect of radiation is clear. However, there may be a relative tendency to report cases involving previous radiation treatment more frequently. It is inevitable that the conclusions of this paper depend on the accuracy and comprehensiveness of reporting.

The population incidence of VS has been calculated to be between 12 and 19 per million people per year.^{3,55} Assuming an even prevalence and an average world population of 6 billion between 1990 and 2014, the number of VSs that develop globally per year would range from 72,000 to 114,000. In relation to the number of cases that have been reported, the chance of developing a spontane-

ous malignancy over 20 years would be 30 in 1.44–2.28 million or between 1.32×10^{-5} and 2.08×10^{-5} . If only the 25 non-NF cases are considered, the chance would be between 1.09×10^{-5} and 1.74×10^{-5} .

In cases of VS treated by radiation the risk needs to be related to the total population treated. According to Leksell Gamma Knife Society (LGKS) reports,³³ the total number of GKSs for VS reported worldwide between 1991 and 2012 was 70,353. A survey by the Acoustic Neuroma Association in 2012 showed that 39% of radiation treatments were fractionated and 61% were single fraction.¹ If one postulates that the proportion of single-fraction treatments represents GKSs and the remaining treatments were delivered by other methods, and if one assumes that the ratio in the United States applies to the rest of the world, then the total number of patients with VS treated by radiation worldwide could be around

TABLE 2: Spontaneous occurrence of malignant vestibular nerve tumors

Authors & Year	Age (yrs), Sex	NF	RT	Histological Type
Best, 1987	24, F	yes	none	triton
Caporlingua et al., 2014	50, F	no	none	triton (?)
Chen et al., 2008	62, F	no	none	MPNST
Earls et al., 1994	NS, NS	NS	NS	melanotic
Gong et al., 2012	55, F	no	none	triton
Gonzalez et al., 2007	43, F	no	NS	MPNST
Gruber et al., 1994	61, F	no	none	MPNST
Han et al., 1992	47, F	no	none	triton
Harada et al., 2000	10, M	no	none	MPNST
Hernanz-Schulman et al., 1986	NS, child	no	none	MPNST
Higami et al., 1998	45, F	yes	none	MPNST
Hong et al., 2014	25, M	no	none	MPNST
Karami et al., 2011	23, F	no	none	MPNST
Kudo et al., 1983	54, M	no	none	MPNST
Kuzmik et al., 2013	73, F	no	none	MPNST
Maeda et al., 1993	38, M	no	none	MPNST
Matsumoto et al., 1990	54, M	no	none	MPNST
Miller et al., 1986	74, M	yes (?)	none	melanotic
Mrak et al., 1994	40, M	no	none	MPNST
Saito et al., 2000	69, M	no	none	melanotic
Scheithauer et al., 2009	32, M	yes	none	MPNST
	26, F	no	none	MPNST
	5, M	no	none	MPNST
Suresh et al., 2003	NS, NS	yes	none	MPNST
Wei et al., 2012	41, F	no	NS	MPNST

115,333. The overall risk of MPNST over 20 years is therefore 29 in 115,333 or 25.1×10^{-5} . If patients with NF are excluded from this analysis, there remain 18 patients whose MPNST was associated with radiation treatment, and thus the risk for malignant transformation in the absence of NF is accordingly 15.6×10^{-5} . This represents a 9 to 14 times increased probability of malignancy in relation to that spontaneous incidence of between 1.09×10^{-5} and 1.74×10^{-5} .

An independent study in patients with NF revealed that in a population of 1348 patients with NF2, 106 would have received radiosurgery.⁵ Malignant transformation occurred in 5 of these cases. This corresponds to a risk of

4717×10^{-5} , a substantially greater risk than that found in patients who do not have NF. We found a greater proportion of patients with NF in the group of patients treated with radiation, which is compatible with the increased susceptibility of NF cases to radiation.

There are certain other prominent differences between cases treated with radiation and cases not treated in this manner. The first is the delay or latency from diagnosis to malignant expression. In cases in which radiation was delivered, this is 68 months (in cases of initial benign disease confirmed by histology) or 85 months (in all cases) compared with 7.2 months in cases in which there was no radiation treatment and there was a prior histological diagnosis

TABLE 3: Malignant transformation of a benign entity

Authors & Year	Age (yrs), Sex	NF	RT	Histological Type	Prior Benign Histological Findings	Latency (mos)
Gousias et al., 2010	64, M	N	none	MPNST	no*	120
McLean et al., 1990	75, M	N	none	MPNST	yes	11
Scheithauer et al., 2009	67, M	N	none	MPNST	yes	9
	56, M	N	none	MPNST	yes	7
Son et al., 2001	33, F	N	none	MPNST	yes	2

* No histology report available, but MR imaging over 120 months clearly shows a benign process that progressed to malignant disease.

of benign disease. This would suggest that the cases involving radiation treatment are showing the delay required by the Cahan criteria for malignant induction, whereas the cases without radiation treatment are already in the process of malignant expression. Table 1 shows that 2 cases involving radiation treatment^{20,25} had an insignificant delay, 6 months for 1 case and 7 months for the other, and therefore may not be cases of true malignant transformation due to radiation, even though one of these patients²⁰ had histologically defined benign disease before SRS.

In addition, the group of patients with previous radiation treatment contains a larger proportion of cases in which histology revealed a sarcomatous element (8 [29.6%] of 27 cases) than the group with no previous radiation treatment (4 [13.3%] of 30 cases). Sarcomatous differentiation is known to be associated with irradiation, and the overall incidence of post-irradiation sarcoma in patients who survive longer than 5 years following radiation therapy is approximately 0.1%.²⁷ This pattern of sarcomatous change also suggests that the malignant progression is due to radiation, although it is appropriate to point out that the rate of malignancy after radiosurgery for VS is 10 times less than that expected after radiation treatment of peripheral bone or soft tissue.²⁷

Finally, there is evidence from the chronology of publications (Table 4) that there has been a 3-fold increase in case reports since the year 2000. If a delay period of 5 to 8 years, according to Cahan's criteria, is added to the decade of 1990, when significant numbers of radiosurgical treatments began to be performed, then an increase in reported cases of MTVS would be expected from 2000 onwards if radiation is a significant predisposing factor for malignant progression. As has been noted earlier, there may be a tendency to report MTVSs more readily than spontaneous malignant VSs. It could also be argued that the armamentarium and expertise of neuropathologists has improved together with a general explosion in the number of published medical papers. Nevertheless, the sudden change in the reported numbers of MTVSs after the year 2000 seems significant.

Although the available information clearly indicates that there is a real chance of malignant transformation due to SRS, both the medical community and patients should be reassured that the risk is very low. The calculations above enumerate the risk value as 15.6×10^{-5} or 0.016% in the absence of NF. This compares favorably with a realistic mortality rate after craniotomy of between 1% and 2%.^{9,49} Although there are a few smaller surgical series of selected cases in which there were no deaths,⁵² it is not re-

alistic to expect a surgical series of 10,000 cases without some mortality, and this is the number of cases required for a comparative result.

Conclusions

Despite more frequent reports of MTVS after radiation therapy, there has been no previous accurate quantification of the risk, except in cases of NF in which the incidence of malignancy is high in relation to the numbers treated. The present review indicates that the risk of malignancy over 20 years in cases in which no radiation was used is 1.32–2.08 per 100,000, and this decreases to 1.09–1.74 per 100,000 if cases of NF are excluded. The analysis of published cases reveals that after radiation treatment the overall risk over 20 years is 25.1 per 100,000, and this decreases to 15.6 per 100,000 if cases of NF are excluded. Radiation treatment therefore increases the risk by approximately 10 times in non-NF cases.

Acknowledgments

We thank Drs. Vasileios Kontopoulos and Anthanasios Kontopoulos for the provision of clinical material.

Disclosure

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author contributions to the study and manuscript preparation include the following. Conception and design: Torrens. Acquisition of data: Torrens, Seferis, Psichidis. Analysis and interpretation of data: Torrens, Paraskevopoulou. Drafting the article: Torrens. Critically revising the article: Paraskevopoulou. Reviewed submitted version of manuscript: Seferis, Psichidis. Approved the final version of the manuscript on behalf of all authors: Torrens.

References

1. Acoustic Neuroma Association: **2012 ANA Patient Survey**. (https://www.anausa.org/resources/patient-surveys/2007-2008-survey-results/doc_download/230-2012-survey-results) [Accessed August 24, 2014]
2. Akamatsu Y, Murakami K, Watanabe M, Jokura H, Tominaga T: Malignant peripheral nerve sheath tumor arising from benign vestibular schwannoma treated by gamma knife radiosurgery after two previous surgeries: a case report with surgical and pathological observations. **World Neurosurg** **73**: 751–754, 2010
3. Babu R, Sharma R, Bagley JH, Hatef J, Friedman AH, Adamson C: Vestibular schwannomas in the modern era: epidemiology, treatment trends, and disparities in management. Clinical article. **J Neurosurg** **119**:121–130, 2013
4. Bari ME, Forster DM, Kemeny AA, Walton L, Hardy D, Anderson JR: Malignancy in a vestibular schwannoma. Report of a case with central neurofibromatosis, treated by both stereotactic radiosurgery and surgical excision, with a review of the literature. **Br J Neurosurg** **16**:284–289, 2002
5. Baser ME, Evans DG, Jackler RK, Sujansky E, Rubenstein A: Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. **Br J Cancer** **82**:998, 2000
6. Best PV: Malignant triton tumour in the cerebellopontine angle. Report of a case. **Acta Neuropathol** **74**:92–96, 1987
7. Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL: Sarcoma arising in irradiated bone: report of eleven cases. 1948. **Cancer** **82**:8–34, 1998

TABLE 4: Cases of malignant VSs presenting over time

Dates of Publication of MPNST Cases	No. of Cases Recorded
1983–1989	4
1990–1994	6
1995–1999	5
2000–2004	14
2005–2009	11
2010–2014	18

8. Caporlingua F, Lapadula G, Antonelli M, Missori P: Pleomorphic rhabdomyosarcoma of the cerebellopontine angle in an adult: a review of literature. **BMJ Case Rep** 2014; bcr2013203257, 2014
9. Cardoso AC, Fernandes YB, Ramina R, Borges G: Acoustic neuroma (vestibular schwannoma): surgical results on 240 patients operated on dorsal decubitus position. **Arq Neuropsiquiatr** 65:605–609, 2007
10. Carlson ML, Babovic-Vuksanovic D, Messiaen L, Scheithauer BW, Neff BA, Link MJ: Radiation-induced rhabdomyosarcoma of the brainstem in a patient with neurofibromatosis type 2. Case report. **J Neurosurg** 112:81–87, 2010 (Erratum in **J Neurosurg** 112:209, 2010)
11. Chen L, Mao Y, Chen H, Zhou LF: Diagnosis and management of intracranial malignant peripheral nerve sheath tumors. **Neurosurgery** 62:825–832, 2008
12. Comey CH, McLaughlin MR, Jho HD, Martinez AJ, Lunsford LD: Death from a malignant cerebellopontine angle triton tumor despite stereotactic radiosurgery. Case report. **J Neurosurg** 89:653–658, 1998
13. Demetriades AK, Saunders N, Rose P, Fisher C, Rowe J, Tranter R, et al: Malignant transformation of acoustic neuroma/vestibular schwannoma 10 years after gamma knife stereotactic radiosurgery. **Skull Base** 20:381–387, 2010
14. Earls JP, Robles HA, McAdams HP, Rao KC: General case of the day. Malignant melanotic schwannoma of the eighth cranial nerve. **Radiographics** 14:1425–1427, 1994
15. Gong L, Liu XY, Zhang WD, Han XJ, Yao L, Zhu SJ, et al: A rare case of malignant triton tumor in the cerebellopontine angle. **Diagn Pathol** 7:43, 2012
16. Gonzalez LF, Lekovic GP, Eschbacher J, Coons S, Spetzler RF: A true malignant schwannoma of the eighth cranial nerve: case report. **Neurosurgery** 61:E421–E422, 2007
17. Gousias K, Boström J, Kovacs A, Niehusmann P, Wagner I, Kristof R: Factors of influence upon overall survival in the treatment of intracranial MPNSTs. Review of the literature and report of a case. **Radiat Oncol** 5:114, 2010
18. Gruber B, Petchenik L, Williams M, Thomas C, Luken MG: Malignant vestibular schwannoma. **Skull Base Surg** 4:227–231, 1994
19. Han DH, Kim DG, Chi JG, Park SH, Jung HW, Kim YG: Malignant triton tumor of the acoustic nerve. Case report. **J Neurosurg** 76:874–877, 1992
20. Hanabusa K, Morikawa A, Murata T, Taki W: Acoustic neuroma with malignant transformation. Case report. **J Neurosurg** 95:518–521, 2001
21. Harada K, Nishizaki T, Adachi N, Suzuki M, Ito H: Pediatric acoustic schwannoma showing rapid regrowth with high proliferative activity. **Childs Nerv Syst** 16:134–137, 2000
22. Hasegawa T, Kida Y, Kato T, Iizuka H, Kuramitsu S, Yamamoto T: Long-term safety and efficacy of stereotactic radiosurgery for vestibular schwannomas: evaluation of 440 patients more than 10 years after treatment with Gamma Knife surgery. Clinical article. **J Neurosurg** 118:557–565, 2013
23. Hernanz-Schulman M, Welch K, Strand R, Ordia JJ: Acoustic neuromas in children. **AJNR Am J Neuroradiol** 7:519–521, 1986
24. Higami Y, Shimokawa I, Kishikawa M, Okimoto T, Ohtani H, Tomita M, et al: Malignant peripheral nerve sheath tumors developing multifocally in the central nervous system in a patient with neurofibromatosis type 2. **Clin Neuropathol** 17:115–120, 1998
25. Ho SY, Kveton JF: Rapid growth of acoustic neuromas after stereotactic radiotherapy in type 2 neurofibromatosis. **Ear Nose Throat J** 81:831–833, 2002
26. Hong W, Cheng H, Wang X, Hu X, Feng C: Study of malignant peripheral nerve sheath tumor in cerebellopontine angle. **J Craniofac Surg** 25:699–701, 2014
27. Inoue YZ, Frassica FJ, Sim FH, Unni KK, Petersen IA, McLeod RA: Clinicopathologic features and treatment of postirradiation sarcoma of bone and soft tissue. **J Surg Oncol** 75:42–50, 2000
28. Karami KJ, Kelkar PS, Verdon MP, Grills IS, Bojrab DI, Pieper DR: Malignant peripheral nerve sheath tumor of the vestibulocochlear nerve and brainstem: multimodality treatment with survival of 27 months. A case report and review of the literature. **Neurosurgery** 69:E1152–E1165, 2011
29. Kubo O, Chernov M, Izawa M, Hayashi M, Muragaki Y, Maruyama T, et al: Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation? **Minim Invasive Neurosurg** 48:334–339, 2005
30. Kudo M, Matsumoto M, Terao H: Malignant nerve sheath tumor of acoustic nerve. **Arch Pathol Lab Med** 107:293–297, 1983
31. Kuzmik GA, Michaelides EM, Chiang VL, Nonaka Y, Fukushima T, Vortmeyer AO, et al: Rapidly progressive epithelioid malignant peripheral nerve sheath tumor of the vestibular nerve. **Otol Neurotol** 34:1739–1742, 2013
32. L'heureux-Lebeau B, Saliba I: Updates on the diagnosis and treatment of intracranial nerve malignant peripheral nerve sheath tumors. **Onco Targets Ther** 6:459–470, 2013
33. Leksell Gamma Knife Society: **Leksell Gamma Knife: Indications Treated 1991 to 2012, 68%-100% of Sites Reporting**. Stockholm: Leksell Gamma Knife Society, 2013
34. Maeda M, Jozaki T, Baba S, Muro H, Shirasawa H, Ichihashi T: Malignant nerve sheath tumor with rhabdomyoblastic differentiation arising from the acoustic nerve. **Acta Pathol Jpn** 43:198–203, 1993
35. Maire JP, Huchet A, Milbeo Y, Darrouzet V, Causse N, Célérier D, et al: Twenty years' experience in the treatment of acoustic neuromas with fractionated radiotherapy: a review of 45 cases. **Int J Radiat Oncol Biol Phys** 66:170–178, 2006
36. Markou K, Eimer S, Perret C, Huchet A, Goudakos J, Liguoro D, et al: Unique case of malignant transformation of a vestibular schwannoma after fractionated radiotherapy. **Am J Otolaryngol** 33:168–173, 2012
37. Matsumoto M, Sakata Y, Sanpei K, Onagi A, Terao H, Kudo M: [Malignant schwannoma of acoustic nerve: a case report.] **No Shinkei Geka** 18:59–62, 1990 (Jpn)
38. McEvoy AW, Kitchen ND: Rapid enlargement of a vestibular schwannoma following gamma knife treatment. **Minim Invasive Neurosurg** 46:254–256, 2003
39. McLean CA, Laidlaw JD, Brownbill DS, Gonzales MF: Recurrence of acoustic neurilemoma as a malignant spindle-cell neoplasm. Case report. **J Neurosurg** 73:946–950, 1990
40. Miller RT, Sarikaya H, Sos A: Melanotic schwannoma of the acoustic nerve. **Arch Pathol Lab Med** 110:153–154, 1986
41. Mrak RE, Flanagan S, Collins CL: Malignant acoustic schwannoma. **Arch Pathol Lab Med** 118:557–561, 1994
42. Muracciole X, Cowen D, Régis J: [Radiosurgery and brain radio-induced carcinogenesis: update.] **Neurochirurgie** 50: 414–420, 2004 (Fr)
43. Newell K, Pollack A: Bilateral cranial nerve VII-VIII malignant peripheral nerve sheath tumors mimicking neurofibromatosis type 2. **J Neuropathol Exp Neurol** 71:593, 2012 (Abstract)
44. Norén G: Long-term complications following gamma knife radiosurgery of vestibular schwannomas. **Stereot Funct Neurosurg** 70 Suppl:165–173, 1998
45. Pollock BE, Lunsford LD, Kondziolka D, Sekula R, Subach BR, Foote RL, et al: Vestibular schwannoma management. Part II. Failed radiosurgery and the role of delayed microsurgery. **J Neurosurg** 89:949–955, 1998
46. Puataweepong P, Janwityanujit T, Larbcharoen N, Dhana-chai M: Radiation-induced peripheral malignant nerve sheath tumor arising from vestibular schwannoma after linac-based stereotactic radiation therapy: a case report and review of literatures. **Case Rep Med** 2012:648191, 2012

47. Rowe J, Grainger A, Walton L, Silcocks P, Radatz M, Kemeny A: Risk of malignancy after gamma knife stereotactic radiosurgery. **Neurosurgery** **60**:60–66, 2007
48. Saito T, Oki S, Mikami T, Kawamoto Y, Yamaguchi S, Kuwamoto K, et al: [Malignant peripheral nerve sheath tumor with divergent cartilage differentiation from the acoustic nerve: case report.] **No To Shinkei** **52**:734–739, 2000 (Jpn)
49. Samii M, Matthies C: Management of 1000 vestibular schwannomas (acoustic neuromas): surgical management and results with an emphasis on complications and how to avoid them. **Neurosurgery** **40**:11–23, 1997
50. Scheithauer BW, Erdogan S, Rodriguez FJ, Burger PC, Woodruff JM, Kros JM, et al: Malignant peripheral nerve sheath tumors of cranial nerves and intracranial contents: a clinicopathologic study of 17 cases. **Am J Surg Pathol** **33**:325–338, 2009
51. Schmitt WR, Carlson ML, Giannini C, Driscoll CL, Link MJ: Radiation-induced sarcoma in a large vestibular schwannoma following stereotactic radiosurgery: case report. **Neurosurgery** **68**:E840–E846, 2011
52. Shahinian HK, Ra Y: 527 fully endoscopic resections of vestibular schwannomas. **Minim Invasive Neurosurg** **54**:61–67, 2011
53. Shin M, Ueki K, Kurita H, Kirino T: Malignant transformation of a vestibular schwannoma after gamma knife radiosurgery. **Lancet** **360**:309–310, 2002
54. Son EI, Kim IM, Kim SP: Vestibular schwannoma with malignant transformation: a case report. **J Korean Med Sci** **16**:817–821, 2001
55. Stangerup SE, Tos M, Thomsen J, Caye-Thomasen P: True incidence of vestibular schwannoma? **Neurosurgery** **67**:1335–1340, 2010
56. Suresh TN, Mahadevan A, Chandrashekhar Sagar B, Santosh V, Yasha TC, Shankar SK: Unusual case of multiple cellular and malignant schwannomas of the cranial and spinal nerves. **Clin Neuropathol** **22**:23–29, 2003
57. Tanbouzi Hussein S, Piccirillo E, Taibah A, Paties CT, Rizoli R, Sanna M: Malignancy in vestibular schwannoma after stereotactic radiotherapy: a case report and review of the literature. **Laryngoscope** **121**:923–928, 2011
58. Thomsen J, Mirz F, Wetke R, Astrup J, Bojsen-Møller M, Nielsen E: Intracranial sarcoma in a patient with neurofibromatosis type 2 treated with gamma knife radiosurgery for vestibular schwannoma. **Am J Otol** **21**:364–370, 2000
59. Van Rompaey K, Michotte A, Ampe B, Moens M, Ates R, Chaskis C, et al: Malignant transformation of a vestibular schwannoma after radiosurgery. **Surg Neurol** **71**:145, 2009 (Abstract)
60. Wei C, Heman-Ackah SE, Newman K, Zagzag D, Golfinos JG, Roland JT Jr: Temporal bone histopathology case of the month: malignant peripheral nerve sheath tumor arising within vestibular schwannoma. **Otol Neurotol** **33**:e83–e84, 2012
61. Wilkinson JS, Reid H, Armstrong GR: Malignant transformation of a recurrent vestibular schwannoma. **J Clin Pathol** **57**:109–110, 2004
62. Yanamadala V, Williamson RW, Fusco DJ, Eschbacher J, Weisskopf P, Porter RW: Malignant transformation of a vestibular schwannoma after gamma knife radiosurgery. **World Neurosurg** **79**:593.e1–593.e8, 2013
63. Yang T, Rockhill J, Born DE, Sekhar LN: A case of high-grade undifferentiated sarcoma after surgical resection and stereotactic radiosurgery of a vestibular schwannoma. **Skull Base** **20**:179–183, 2010

Manuscript submitted June 12, 2014.

Accepted July 17, 2014.

Please include this information when citing this paper: DOI: 10.3171/2014.7.GKS141311.

Address correspondence to: Michael Torrens, F.R.C.S., Department of Neurosurgery, Hygeia Hospital, 4 Erythrou Stavrou, Maroussi, 15123 Athens, Greece. email: m.torrens@hygeia.gr.